Jonas Heilskov Graversen obtained a PhD in Molecular Biology from Aarhus University in 2000. He continued as an innovation postdoc at Aarhus University. From 2003-2014 Jonas H. Graversen worked in the medical/biotech industry. Here he gained extensive experience in medical discovery, translational research, and planning transition from discovery into early development phase. He is co-founder of four biotech companies, one exit accomplished. He has several years of experience in managing drug discovery projects, both within academia and in biotech, and has served as daily manager of scientific teams in both academia and industry. In 2014 he joined Department of Molecular Medicine at the University of Southern Denmark.
His laboratory works extensively on receptor characterization and drug targeting using specific receptors as gateways. Specific targeting of drugs to the liver and selected cells of the liver is an attractive approach for exploiting the plasticity of the liver. Thus, the vision is to be able to modulate pathways and specific cellular markers elucidated in the ATLAS project to develop novel treatment modalities for liver diseases, especially those related to obesity and inflammation.